Tumour-agnostic drugs in paediatric cancers.

Chisholm, Julia C; Carceller, Fernando; Marshall, Lynley V

Chisholm, Julia C; Carceller, Fernando; Marshall, Lynley V.

Afiliação

Chisholm JC; Paediatric and Adolescent Oncology Drug Development Team, Children and Young People's Unit, Royal Marsden Hospital and Institute of Cancer Research, Sutton, UK. julia.chisholm@rmh.nhs.uk.
Carceller F; Paediatric and Adolescent Oncology Drug Development Team, Children and Young People's Unit, Royal Marsden Hospital and Institute of Cancer Research, Sutton, UK.
Marshall LV; Paediatric and Adolescent Oncology Drug Development Team, Children and Young People's Unit, Royal Marsden Hospital and Institute of Cancer Research, Sutton, UK.

Br J Cancer ; 122(10): 1425-1427, 2020 05.

Article em En | MEDLINE | ID: mdl-32161367

ABSTRACT

ABSTRACT

The recognition that new cancer drugs can be truly tumour-agnostic based on mechanism-of-action is important for paediatric cancers, where access to novel targeted therapies developed for adult indications has sometimes been problematic. The recently approved drug larotrectinib is an excellent case study of the development of a tumour-agnostic drug relevant to children.

Assuntos

Neoplasias/tratamento farmacológico; Proteínas de Fusão Oncogênica/efeitos dos fármacos; Pediatria; Adulto; Antineoplásicos/uso terapêutico; Criança; Aprovação de Drogas; Humanos; Neoplasias/epidemiologia; Neoplasias/genética; Preparações Farmacêuticas; Inibidores de Proteínas Quinases/uso terapêutico; Pirazóis/uso terapêutico; Pirimidinas/uso terapêutico

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pediatria / Proteínas de Fusão Oncogênica / Neoplasias Limite: Adult / Child / Humans Idioma: En Revista: Br J Cancer Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google